CN117396193A - 用于递送rna的组合物和方法 - Google Patents

用于递送rna的组合物和方法 Download PDF

Info

Publication number
CN117396193A
CN117396193A CN202280026001.6A CN202280026001A CN117396193A CN 117396193 A CN117396193 A CN 117396193A CN 202280026001 A CN202280026001 A CN 202280026001A CN 117396193 A CN117396193 A CN 117396193A
Authority
CN
China
Prior art keywords
composition
lnp
tert
lipid
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280026001.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·拉姆那斯
G·J·马尔可夫
W·G·奥尔森
K·D·布鲁尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recycling Technology Co ltd
Original Assignee
Recycling Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recycling Technology Co ltd filed Critical Recycling Technology Co ltd
Publication of CN117396193A publication Critical patent/CN117396193A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280026001.6A 2021-03-31 2022-03-30 用于递送rna的组合物和方法 Pending CN117396193A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163169118P 2021-03-31 2021-03-31
US63/169,118 2021-03-31
PCT/US2022/022642 WO2022212576A1 (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna

Publications (1)

Publication Number Publication Date
CN117396193A true CN117396193A (zh) 2024-01-12

Family

ID=83456716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280026001.6A Pending CN117396193A (zh) 2021-03-31 2022-03-30 用于递送rna的组合物和方法

Country Status (8)

Country Link
US (1) US20220347112A1 (cg-RX-API-DMAC10.html)
EP (1) EP4312942A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024513048A (cg-RX-API-DMAC10.html)
CN (1) CN117396193A (cg-RX-API-DMAC10.html)
AU (1) AU2022246851A1 (cg-RX-API-DMAC10.html)
CA (1) CA3215112A1 (cg-RX-API-DMAC10.html)
IL (1) IL307319A (cg-RX-API-DMAC10.html)
WO (1) WO2022212576A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771213A (zh) * 2023-01-10 2024-03-29 北京剂泰医药科技有限公司 脂质纳米颗粒组合物及其用途
TW202509222A (zh) * 2023-05-08 2025-03-01 美商默沙東有限責任公司 編碼諾羅病毒vp1抗原之多核苷酸及其用途
WO2025049632A1 (en) * 2023-08-29 2025-03-06 Rejuvenation Technologies Inc. Compositions and methods for broad delivery of rna to tissue
WO2025255027A1 (en) * 2024-06-03 2025-12-11 Flagship Labs 114, Inc. Lipid nanoparticles for topical delivery
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026010842A1 (en) * 2024-07-01 2026-01-08 The Trustees Of The University Of Pennsylvania Use of lipid nanoparticle mrna for tert specific cancer immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10525075B2 (en) * 2013-02-22 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Compounds, compositions, methods, and kits relating to telomere extension
IL270631B2 (en) * 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
CA3094057C (en) * 2018-03-27 2025-04-08 Nof Corporation CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CA3124524A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use

Also Published As

Publication number Publication date
CA3215112A1 (en) 2022-10-06
EP4312942A1 (en) 2024-02-07
WO2022212576A1 (en) 2022-10-06
AU2022246851A1 (en) 2023-10-12
JP2024513048A (ja) 2024-03-21
AU2022246851A9 (en) 2023-10-26
EP4312942A4 (en) 2025-03-19
US20220347112A1 (en) 2022-11-03
IL307319A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
EP3852728B1 (en) Preparation of lipid nanoparticles and methods of administration thereof
AU2016369612B2 (en) Polynucleotides encoding methylmalonyl-CoA mutase
EP3595727B1 (en) Lipid nanoparticle formulation
RU2769316C2 (ru) Полинуклеотиды, кодирующие интерлейкин-12 (il12), и их применения
AU2014329452B2 (en) Polynucleotides encoding low density lipoprotein receptor
AU2021203492A1 (en) Nucleic acid vaccines
US20190192653A1 (en) Compositions and methods for tolerizing cellular systems
CN113939282A (zh) 制备脂质纳米颗粒的方法
US20220347112A1 (en) Compositions and methods for delivery of rna
JP2020520640A (ja) 連結したインターロイキン−12(il12)ポリペプチドをコードするポリヌクレオチド及びその使用
CA3027201A1 (en) Stabilized formulations of lipid nanoparticles
CA2923029A1 (en) Chimeric polynucleotides
CA2955375A1 (en) Terminal modifications of polynucleotides
CN113412273B (zh) 用于治疗原发性纤毛运动障碍的组合物和方法
JP2020522244A (ja) 糖原病iii型のための治療薬
CN116916936A (zh) 用于递送rna的组合物和方法
HK40101750A (en) Compositions and methods for delivery of rna
HK40099690A (en) Compositions and methods for delivery of rna
AU2023334154A1 (en) Compositions and methods for delivery of rna
EP4622679A1 (en) Targeted delivery of gene editing constructs and methods of use thereof
WO2026010842A1 (en) Use of lipid nanoparticle mrna for tert specific cancer immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101750

Country of ref document: HK